- Naranj Research Desk
- 🇸🇦 Saudi Stock Market
- 🇺🇸 USA Stock Market
GILD — NASDAQ —
Current RSI of this stock is 70.41, which indicates the strength of buyers.
Increasing ADX value above 20, indicated the strength of the trend, thereby uptrending ADX confirms the bullish or bearish supportive decisions. Along with the rising ADX, and the +DI is above (or crossing) -DI, indicates the long trades should be favoured.
Based on our swing stock trading advice in USA, Gilead Sciences stock price target will be USD 92 - USD 93 in the next 12-14 trading sessions.
Gilead Sciences, Inc. is a biopharmaceutical firm focused on discovering, developing, and marketing medicines for unmet medical needs globally, including the U.S. and Europe. It offers products like Biktarvy, Genvoya, and Truvada for HIV/AIDS, Veklury for COVID-19, and Epclusa for viral hepatitis. Additionally, it provides Yescarta and Tecartus for oncology, Letairis for pulmonary arterial hypertension, and AmBisome for serious fungal infections. The company collaborates with various firms, including Arcus Biosciences and Merck, and has a research agreement with Merus N.V. Founded in 1987, it is based in Foster City, California.
GILD — NASDAQ —
Current RSI of this stock is 70.41, which indicates the strength of buyers.
Increasing ADX value above 20, indicated the strength of the trend, thereby uptrending ADX confirms the bullish or bearish supportive decisions. Along with the rising ADX, and the +DI is above (or crossing) -DI, indicates the long trades should be favoured.
Based on our swing stock trading advice in USA, Gilead Sciences stock price target will be USD 92 - USD 93 in the next 12-14 trading sessions.
